Kynam Capital Management, LP Puma Biotechnology, Inc. Transaction History

Kynam Capital Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$2.63 - $4.09 $2,380 - $3,701	905 Added 0.19%	473,975 $1.25 Million
Q1 2023 May 15, 2023	SELL	$2.21 - $4.82 $195,671 - $426,757	-88,539 Reduced 15.77%	473,070 $1.46 Million
Q4 2022 Feb 14, 2023	BUY	$2.12 - $5.08 $3,900 - $9,347	1,840 Added 0.33%	561,609 $2.38 Million
Q3 2022 Nov 14, 2022	SELL	$2.27 - $3.84 $45,731 - $77,360	-20,146 Reduced 3.47%	559,769 $1.33 Million
Q2 2022 Aug 15, 2022	SELL	$1.64 - $3.3 $120,589 - $242,649	-73,530 Reduced 11.25%	579,915 $1.65 Million
Q1 2022 May 13, 2022	SELL	$2.13 - $3.24 $64,270 - $97,763	-30,174 Reduced 4.41%	653,445 $1.88 Million
Q4 2021 Feb 14, 2022	BUY	$2.85 - $6.58 $1.95 Million - $4.5 Million	683,619 New	683,619 $2.08 Million

102

29.1M

60.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $127M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Kynam Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Kynam Capital Management, LP with notifications on news.